Close Monitoring, Full-Time Caregiver Recommended for 30 Days After CAR-T Therapy
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Structured palliative care can ensure these patients and their caregivers have an optimal experience that does not hinder trial outcomes.
Estimated 785 fewer cancer deaths in 2017 in states that expanded Medicaid.
A patient education and monitoring program improved patients’ ability to manage and report adverse events related to treatment with ICIs.
Progression-free and overall survival were worse among patients with HLH receiving CAR-T cell therapy by 10-month follow-up.
Obinutuzumab plus chemotherapy showed more durable efficacy, safety, and longer progression-free survival for patients with untreated follicular lymphoma.
Promising follow-up data on safety and efficacy of fixed-duration venetoclax-obinutuzumab for patients with untreated CLL.
Only 2 patients received hydroxychloroquine as part of a clinical trial, and about 10% were taking the drug at the time of their COVID-19 presentation.
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
Patients undergoing allogeneic stem cell transplantation who experience C difficile infections may have an increased risk for graft vs host disease.